Loading
Sugemalimab is CStone's PD-L1 antibody, approved in China for first-line lung cancer with chemotherapy and after chemoradiotherapy in stage III disease, and the first China-developed PD-L1 antibody to win European approval.
GEMSTONE-302 (479 patients, squamous and non-squamous metastatic NSCLC) gave a progression-free survival hazard ratio of 0.50 versus placebo plus platinum chemotherapy, the basis of the NMPA approval in December 2021. GEMSTONE-301 added unresectable stage III NSCLC after concurrent or sequential chemoradiotherapy in 2022, and relapsed or refractory extranodal NK/T-cell lymphoma followed. The European Commission approved sugemalimab with platinum chemotherapy for first-line metastatic NSCLC without EGFR, ALK, ROS1 or RET alterations in July 2024, making it the first anti-PD-L1 antibody from a Chinese company approved in the EU.
Fully human anti-PD-L1 IgG4 antibody generated in the OmniRat platform; blocks PD-L1 binding to PD-1 and B7-1. Connects to PD-L1.
1.Sugemalimab binds PD-L1.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| China | 2021 | First-line metastatic squamous and non-squamous NSCLC with platinum chemotherapy (GEMSTONE-302) |
| China | 2022 | Unresectable stage III NSCLC without progression after chemoradiotherapy (GEMSTONE-301) |
| EU | 2024 | First-line metastatic NSCLC with platinum chemotherapy, no sensitising EGFR, ALK, ROS1 or RET alterations |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Sugemalimab" OR ABSTRACT:"Sugemalimab" OR TITLE:"Cejemly" OR ABSTRACT:"Cejemly" OR TITLE:"CS1001" OR ABSTRACT:"CS1001") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sugemalimab, not a curated reading list.
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Monoclonal antibodies, Immune checkpoint inhibitors and the tag china.
Shares Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag china.
Shares Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag china.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag china.
Shares Non-small-cell lung cancer and the tag china.
Shares Immune checkpoint inhibitors and the tag china.
Shares Monoclonal antibodies and the tag china.
Shares CD80 (B7-1), PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Monoclonal antibodies and the tag china.